{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T06:08:41Z","timestamp":1768457321311,"version":"3.49.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002336","name":"Daiichi Sankyo Co.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"JSPS","doi-asserted-by":"publisher","award":["JP17H04309"],"award-info":[{"award-number":["JP17H04309"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.bone.2020.115331","type":"journal-article","created":{"date-parts":[[2020,3,23]],"date-time":"2020-03-23T12:27:28Z","timestamp":1584966448000},"page":"115331","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Siglec-15-targeting therapy protects against glucocorticoid-induced osteoporosis of growing skeleton in juvenile rats"],"prefix":"10.1016","volume":"135","author":[{"given":"Dai","family":"Sato","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2436-2175","authenticated-orcid":false,"given":"Masahiko","family":"Takahata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Ota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chie","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0309-6637","authenticated-orcid":false,"given":"Tomoka","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomomaya","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norio","family":"Amizuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eisuke","family":"Tsuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Okada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiharu","family":"Hiruma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norimasa","family":"Iwasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2020.115331_bb0005","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1007\/s00198-016-3515-9","article-title":"The management of osteoporosis in children","volume":"27","author":"Ward","year":"2016","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2020.115331_bb0010","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s40265-017-0715-3","article-title":"Pediatric osteoporosis: diagnosis and treatment considerations","volume":"77","author":"Marrani","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.bone.2020.115331_bb0015","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nrrheum.2013.45","article-title":"Causes, mechanisms, and management of paediatric osteoporosis","volume":"9","author":"Makitie","year":"2013","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.bone.2020.115331_bb0020","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.jocd.2014.01.005","article-title":"Bone health in children and adolescents with chronic diseases that may affect the skeleton: the 2013 ISCD pediatric official positions","volume":"17","author":"Bianchi","year":"2014","journal-title":"J. Clin. Densitom."},{"key":"10.1016\/j.bone.2020.115331_bb0025","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"FREEDOM trial, Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2020.115331_bb0030","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1002\/jbmr.2511","article-title":"Canadian STeroid-Associated Osteoporosis in Pediatric Population (STOPP) Consortium, incident vertebral fractures and risk factors in the first three years following glucocorticoid initiation among pediatric patients with rheumatic disorders","volume":"30","author":"LeBlanc","year":"2015","journal-title":"J. Bone Miner. Res."},{"issue":"1","key":"10.1016\/j.bone.2020.115331_bb0035","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1474-4422(09)70271-6","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management","volume":"9","author":"Bushby","year":"2010","journal-title":"Lancet Neurol."},{"issue":"3","key":"10.1016\/j.bone.2020.115331_bb0040","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1053\/j.seminhematol.2013.06.007","article-title":"A 50-year journey to cure childhood acute lymphoblastic leukemia","volume":"50","author":"Pui","year":"2013","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.bone.2020.115331_bb0045","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S8756-3282(01)00610-X","article-title":"Molecular mechanisms of glucocorticoid-induced osteoporosis","volume":"29","author":"Patschan","year":"2001","journal-title":"Bone"},{"key":"10.1016\/j.bone.2020.115331_bb0050","first-page":"CD005324","article-title":"Bisphosphonate therapy for children and adolescents with secondary osteoporosis","volume":"4","author":"Ward","year":"2007","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.bone.2020.115331_bb0055","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005088.pub3","article-title":"Bisphosphonate therapy for osteogenesis imperfecta","volume":"7","author":"Dwan","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.bone.2020.115331_bb0060","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.bone.2018.07.026","article-title":"Siglec-15-targeting therapy increases bone mass in rats without impairing skeletal growth","volume":"116","author":"Sato","year":"2018","journal-title":"Bone"},{"key":"10.1016\/j.bone.2020.115331_bb0065","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.bone.2012.11.036","article-title":"Impaired osteoclast differentiation and function and mild osteopetrosis development in Siglec-15-deficient mice","volume":"53","author":"Hiruma","year":"2013","journal-title":"Bone"},{"key":"10.1016\/j.bone.2020.115331_bb0070","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.bbrc.2011.05.015","article-title":"Siglec-15, a member of the sialic acid-binding lectin, is a novel regulator for osteoclast differentiation","volume":"409","author":"Hiruma","year":"2011","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bone.2020.115331_bb0075","doi-asserted-by":"crossref","first-page":"17493","DOI":"10.1074\/jbc.M111.324194","article-title":"Siglec-15 protein regulates formation of functional osteoclasts in concert with DNAX-activating protein of 12\u00a0kDa (DAP12)","volume":"287","author":"Ishida-Kitagawa","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bone.2020.115331_bb0080","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1002\/jbmr.1989","article-title":"Siglec-15 regulates osteoclast differentiation by modulating RANKL-induced phosphatidylinositol 3-kinase\/Akt and Erk pathways in association with signaling adaptor DAP12","volume":"28","author":"Kameda","year":"2013","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115331_bb0085","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1242\/jcs.069872","article-title":"Cytoskeletal dysfunction dominates in DAP12-deficient osteoclasts","volume":"123","author":"Zou","year":"2010","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.bone.2020.115331_bb0090","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/bonekey.2014.47","article-title":"Instructions for producing a mouse model of glucocorticoid-induced osteoporosis","volume":"3","author":"Thiele","year":"2014","journal-title":"Bonekey Rep"},{"key":"10.1016\/j.bone.2020.115331_bb0095","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/jbmr.5650050312","article-title":"Aminohydroxybutane bisphosphonate inhibits bone loss due to immobilization in rats","volume":"5","author":"Thompson","year":"1990","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115331_bb0100","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/jbmr.5650060405","article-title":"The bisphosphonate alendronate (MK-217) inhibits bone loss due to ovariectomy in rats","volume":"6","author":"Seedor","year":"1991","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115331_bb0105","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/S0022-3565(24)37566-4","article-title":"Effects of continuous alendronate treatment on bone mass and mechanical properties in ovariectomized rats: comparison with pamidronate and etidronate in growing rats","volume":"286","author":"Azuma","year":"1998","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bone.2020.115331_bb0110","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1002\/jbmr.141","article-title":"Guidelines for assessment of bone microstructure in rodents using micro-computed tomography","volume":"25","author":"Bouxsein","year":"2010","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115331_bb0115","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1359\/jbmr.2003.18.7.1217","article-title":"Dietary calcium and phosphorus ratio regulates bone mineralization and turnover in vitamin D receptor knockout mice by affecting intestinal calcium and phosphorus absorption","volume":"18","author":"Masuyama","year":"2003","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115331_bb0120","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S8756-3282(99)00212-4","article-title":"Long-term therapy of ovariectomy-induced osteopenia with parathyroid hormone analog SDZ PTS 893 and bone maintenance in retired breeder rats","volume":"25","author":"Thomsen","year":"1999","journal-title":"Bone"},{"key":"10.1016\/j.bone.2020.115331_bb0125","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1093\/rheumatology\/keh538","article-title":"Effects of once-weekly oral alendronate on bone in children on glucocorticoid treatment","volume":"44","author":"Rudge","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.bone.2020.115331_bb0130","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.eclinm.2019.06.004","article-title":"British Society for Paediatric and Adolescent Rheumatology UK, the prevention and treatment of glucocorticoid-induced osteopaenia in juvenile rheumatic disease: a randomised double-blind controlled trial","volume":"12","author":"Rooney","year":"2019","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.bone.2020.115331_bb0135","doi-asserted-by":"crossref","first-page":"6498","DOI":"10.1074\/jbc.M113.494542","article-title":"Mechanism and function of monoclonal antibodies targeting siglec-15 for therapeutic inhibition of osteoclastic bone resorption","volume":"289","author":"Stuible","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bone.2020.115331_bb0140","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s00223-014-9865-4","article-title":"A comparison of osteoclast-rich and osteoclast-poor osteopetrosis in adult mice sheds light on the role of the osteoclast in coupling bone resorption and bone formation","volume":"95","author":"Thudium","year":"2014","journal-title":"Calcif. Tissue Int."},{"issue":"Suppl. 2","key":"10.1016\/j.bone.2020.115331_bb0145","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/rheumatology\/32.suppl_2.27","article-title":"Glucocorticoid effects on statural growth","volume":"32","author":"Avioli","year":"1993","journal-title":"Br. J. Rheumatol."},{"key":"10.1016\/j.bone.2020.115331_bb0150","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S0889-8529(05)70348-0","article-title":"Growth suppression by glucocorticoid therapy","volume":"25","author":"Allen","year":"1996","journal-title":"Endocrinol. Metab. Clin. N. Am."},{"key":"10.1016\/j.bone.2020.115331_bb0155","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1210\/endo.134.1.7506213","article-title":"Reduced chondroclast differentiation results in increased cancellous bone volume in estrogen-treated growing rats","volume":"134","author":"Turner","year":"1994","journal-title":"Endocrinology"},{"key":"10.1016\/j.bone.2020.115331_bb0160","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1177\/43.5.7730591","article-title":"The septoclast, a cathepsin B-rich cell involved in the resorption of growth plate cartilage","volume":"43","author":"Lee","year":"1995","journal-title":"J. Histochem. Cytochem."},{"key":"10.1016\/j.bone.2020.115331_bb0165","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/nature02444","article-title":"Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis","volume":"428","author":"Koga","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.bone.2020.115331_bb0170","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1359\/JBMR.0301234","article-title":"The signaling adapter protein DAP12 regulates multinucleation during osteoclast development","volume":"19","author":"Humphrey","year":"2004","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115331_bb0175","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1159\/000324642","article-title":"The nature and role of periosteum in bone and cartilage regeneration","volume":"194","author":"Matsushima","year":"2011","journal-title":"Cells Tissues Organs"},{"key":"10.1016\/j.bone.2020.115331_bb0180","doi-asserted-by":"crossref","first-page":"3649","DOI":"10.1002\/art.34639","article-title":"Mechanisms of bone fragility in a mouse model of glucocorticoid-treated rheumatoid arthritis: implications for insufficiency fracture risk","volume":"64","author":"Takahata","year":"2012","journal-title":"Arthritis Rheum."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328220301113?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328220301113?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T17:46:57Z","timestamp":1757612817000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328220301113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":36,"alternative-id":["S8756328220301113"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2020.115331","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Siglec-15-targeting therapy protects against glucocorticoid-induced osteoporosis of growing skeleton in juvenile rats","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2020.115331","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115331"}}